IBT in collaboration with Dr. Daniel Nelson’s lab at University of Tulane National Primate Center received a collaborative Phase II STTR grant from NIH, entitled Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

This Phase II Project builds upon successfully completed Phase I studies that showed proof of concept for a highly promising therapeutic strategy. This strategy is based on a novel technology that uses Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb) that are directed to the site of B. anthracis infection. In this Phase II project, Dr. Adhikari of IBT and collaborators will select a final product candidate based on the efficacy studies in mouse and NHP, as well as extended PK and stability studies.  Work under this project further includes computer-aided optimization of the lead ISTAb candidates and selection based on efficacy in rodents and nonhuman primates, as well as analytical development.